English
Keenova Therapeutics plc
EDGARMarket value is not computed: no recent price is available.
248 filing records in this dataset, filed from 2013-08-12 to 2026-11-10. Reported financial figures are available; chart coverage varies by period.
Holdings and insider activity
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 12 transactions, 2,509,842 shares
- Sum of shares × price per share: 226,615,177.5
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
- 2026-11-10 GOLDENTREE ASSET MANAGEMENT LP P 120,652 91.00
- 2026-11-09 GOLDENTREE ASSET MANAGEMENT LP P 30,000 89.25
- 2026-11-06 GOLDENTREE ASSET MANAGEMENT LP P 150,000 89.25
- 2026-11-05 GOLDENTREE ASSET MANAGEMENT LP P 145,716 89.25
- 2026-10-14 GOLDENTREE ASSET MANAGEMENT LP P 137,000 90.00
5% holders (Schedule 13D and 13G)
- GoldenTree Asset Management LP 22.3% SCHEDULE 13D/A 11/06/2026
- GoldenTree Asset Management LLC 22.3% SCHEDULE 13D/A 11/06/2026
- Steven A. Tananbaum 22.4% SCHEDULE 13D/A 11/06/2026
Institutional holders (Form 13F)
Trades by members of Congress
Short annual reporting periods
These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.
Corrected figures
| Measure | Period | Value |
|---|---|---|
| Capital expenditure | 2023-11-15 – 2023-12-29 | 2200000 USD Source Dispute |
| Cost of revenue | 2023-11-15 – 2023-12-29 | 84900000 USD Source Dispute |
| Gross profit | 2023-11-15 – 2023-12-29 | 54900000 USD Source Dispute |
| Net income | 2023-11-15 – 2023-12-29 | -38200000 USD Source Dispute |
| Operating cash flow | 2023-11-15 – 2023-12-29 | 73400000 USD Source Dispute |
| Operating income | 2023-11-15 – 2023-12-29 | -16900000 USD Source Dispute |
| Research and development | 2023-11-15 – 2023-12-29 | 11800000 USD Source Dispute |
| Selling, general and administrative | 2023-11-15 – 2023-12-29 | 56000000 USD Source Dispute |
| Capital expenditure | 2022-06-17 – 2022-12-30 | 28800000 USD Source Dispute |
| Cost of revenue | 2022-06-17 – 2022-12-30 | 991000000 USD Source Dispute |
| Gross profit | 2022-06-17 – 2022-12-30 | 48700000 USD Source Dispute |
| Net income | 2022-06-17 – 2022-12-30 | -598100000 USD Source Dispute |
| Operating cash flow | 2022-06-17 – 2022-12-30 | 47100000 USD Source Dispute |
| Operating income | 2022-06-17 – 2022-12-30 | -316700000 USD Source Dispute |
| Research and development | 2022-06-17 – 2022-12-30 | 64200000 USD Source Dispute |
| Selling, general and administrative | 2022-06-17 – 2022-12-30 | 268900000 USD Source Dispute |
- Cash and cash equivalents
- 1.09 billion USD Source
Exact value
1085600000 USD
- Long-term debt including current maturities
- 3.58 billion USD Derived
- Shares outstanding
- 19.7 million shares Source
Exact value
19736759 shares
Reported share-count change
0.21% · 40.4 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-10.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 8 of 11 periods available· newest 2025-12-31
- Net income: 8 of 11 periods available· newest 2025-12-31
- Operating cash flow: 8 of 11 periods available· newest 2025-12-31
- Capital expenditure: 8 of 11 periods available· newest 2025-12-31
- Total assets: 8 of 11 periods available· newest 2025-12-31
- Total liabilities: 8 of 11 periods available· newest 2025-12-31
- Current assets: 8 of 11 periods available· newest 2025-12-31
- Current liabilities: 8 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 7 of 11 periods available· newest 2024-12-27
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
-202.4%Prior period
USD 477.9 million
–
Current period
−USD 489.5 million
–
Exact inputs and evidence
-489500000 − 477900000 = -967400000 USD
477900000 USD · 2023-12-30 – 2024-12-27
Inspect prior input Prior source-489500000 USD · 2024-12-28 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 173 millionPrior period
−USD 48 million
–
Current period
USD 125 million
–
Exact inputs and evidence
125000000 − -48000000 = 173000000 USD
-48000000 USD · 2023-12-30 – 2024-12-27
Inspect prior input Prior source125000000 USD · 2024-12-28 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-8%Prior period
USD 54.8 million
–
Current period
USD 50.4 million
–
Exact inputs and evidence
50400000 − 54800000 = -4400000 USD
54800000 USD · 2023-12-30 – 2024-12-27
Inspect prior input Prior source50400000 USD · 2024-12-28 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2015-09-26 – 2016-09-30 | USD 643.7 million Exact valueExact value: 643700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.18 billion Exact valueExact value: 1184600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 182.9 million Exact valueExact value: 182900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1 billion Calculation and evidence1184600000 − 182900000 USD Exact free cash flow: 1001700000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2016-12-31 – 2017-12-29 | USD 2.13 billion Exact valueExact value: 2134400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 727.3 million Exact valueExact value: 727300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 186.1 million Exact valueExact value: 186100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 541.2 million Calculation and evidence727300000 − 186100000 USD Exact free cash flow: 541200000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2017-12-30 – 2018-12-28 | −USD 3.61 billion Exact valueExact value: -3607000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 665.5 million Exact valueExact value: 665500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 127 million Exact valueExact value: 127000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 538.5 million Calculation and evidence665500000 − 127000000 USD Exact free cash flow: 538500000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2019 2018-12-29 – 2019-12-27 | −USD 996.5 million Exact valueExact value: -996500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 742.9 million Exact valueExact value: 742900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 133 million Exact valueExact value: 133000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 609.9 million Calculation and evidence742900000 − 133000000 USD Exact free cash flow: 609900000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2019-12-28 – 2020-12-25 | −USD 944.6 million Exact valueExact value: -944600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 498.9 million Exact valueExact value: 498900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 47.7 million Exact valueExact value: 47700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 451.2 million Calculation and evidence498900000 − 47700000 USD Exact free cash flow: 451200000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2020-12-26 – 2021-12-31 | −USD 717.4 million Exact valueExact value: -717400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 455.4 million Exact valueExact value: 455400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 55.3 million Exact valueExact value: 55300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 400.1 million Calculation and evidence455400000 − 55300000 USD Exact free cash flow: 400100000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2023-12-30 – 2024-12-27 | USD 477.9 million Exact valueExact value: 477900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 48 million Exact valueExact value: -48000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 54.8 million Exact valueExact value: 54800000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 102.8 million Calculation and evidence-48000000 − 54800000 USD Exact free cash flow: -102800000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2024-12-28 – 2025-12-31 | −USD 489.5 million Exact valueExact value: -489500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 125 million Exact valueExact value: 125000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 50.4 million Exact valueExact value: 50400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 74.6 million Calculation and evidence125000000 − 50400000 USD Exact free cash flow: 74600000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
248 filings · 4,283 latest values · 4,283 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001567892, 1567892, MNK, MNKKQ(1), MNKTQ (1), edgar:1567892
Also known as Keenova Therapeutics plc, Mallinckrodt plc